ArticleArchives of rheumatology2025
Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploratory Real-World Observations on Pulmonary Function Evolution, HRCT Patterns, and Antifibrotic Escalation in Systemic Sclerosis-Associated Interstitial Lung Disease Treated with Mycophenolate Mofetil.Journal of clinical medicine · 2026Article
- Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Several clinical studies have shown favorable outcomes in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD), yet head-to-head comparisons regarding the efficacy and safety of these pharmacological therapies remain limited. Materials and Methods: A systematical search was conducted to identify randomized controlled trials (RCTs) on pharmacological treatments for SScILD.A comprehensive systematic search was performed across Cochrane Library, Embase, PubMed, and Web of Science to identify RCTs that evaluated pharmacological interventions for SSc-ILD, specifically cyclophosphamide, mycophenolate mofetil, nintedanib, pirfenidone, tocilizumab, and rituximab. The effects of various treatments versus placebo on changes in forced vital capacity (FVC), diffusing capacity of the lungs for carbon monoxide (DLCO), and serious adverse events (SAEs) were evaluated by a Bayesian network meta-analysis. Pooled estimates, including mean difference and risk ratios with 95% CIs, were calculated to compare different therapies. The surface under the cumulative ranking probability (SUCRA) was then used to rank these therapeutic agents. Results: Tocilizumab had the highest SUCRA probability (90.4%) in slowing the deterioration of FVC. Rituximab showed the highest SUCRA probability (84.2%) in the prevention of DLCO. Moreover, rituximab showed the lowest probability (59.1%) for SAEs. Conclusion: Tocilizumab and rituximab may be the optimal interventions. Still, further direct head-to-head trials are necessary to substantiate these conclusions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.